Zacks Investment Research upgraded shares of SLS International (AMEX:SLS) from a sell rating to a hold rating in a research report released on Wednesday morning, reports.

According to Zacks, “SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company’s product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. “

A number of other brokerages have also weighed in on SLS. Maxim Group lowered shares of SLS International from a buy rating to a hold rating in a report on Friday, March 22nd. Alliance Global Partners began coverage on shares of SLS International in a report on Monday, April 8th. They set a buy rating and a $4.50 price objective on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $5.55.

SLS International Company Profile

SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards.

See Also: Yield Curve

Get a free copy of the Zacks research report on SLS International (SLS)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for SLS International (AMEX:SLS)

Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with's FREE daily email newsletter.